Meta AnalysisID 6788
金水宝胶囊、百令胶囊与至灵胶囊治疗慢性阻塞性肺疾病(COPD)疗效的网状Meta分析
CRD42023425989
Jinshuibao capsule, Bailing capsule, and Zhiling capsule are oral preparations of fermented cordyceps powder, which are widely used in the treatment of chronic obstructive pulmonary disease (COPD) in traditional Chinese
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Formula: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 6788
- Evidence Id
- 15346
- Core Evidence Id
- 15346
- Source Meta Analysis Id
- 6772
- Herb2 Meta Analysis Id
- HBMA006772
- Crd Id
- CRD42023425989
- Title
- Efficacy of Jinshuibao capsule, Bailing capsule, and Zhiling capsule in the therapy of chronic obstructive pulmonary disease (COPD) based on network meta-analysis
- Review Question
- Jinshuibao capsule, Bailing capsule, and Zhiling capsule are oral preparations of fermented cordyceps powder, which are widely used in the treatment of chronic obstructive pulmonary disease (COPD) in traditional Chinese medicine. The purpose of this study is to compare the efficacy of three cordyceps preparations (Jinshuibao capsule, Bailing capsule, Zhiling capsule) on COPD by network meta-analysis.
- Study Type Included
- Randomized controlled trials (RCTs) in patients with GOLD stage 2-3 COPD: the criteria for GOLD stage 2-3 were postbronchodilator FEV1>30% and<80% predicted, according to Global Initiative for Chronic Obstructive Lung Disease in 2010 or Guideline in China.
- Condition Being Studied
- Chronic obstructive pulmonary disease (COPD) is a widespread illness. It is primarily characterized by bronchial obstruction and inflammation of the chronic airway, which results in gradually impeding the airflow. Globally, COPD is ranked as the third leading cause of fatalities. As a critical health problem, COPD is a primary cause of chronic morbidity and mortality. Most patients suffer from COPD for years and pass away prematurely due to the disease itself or complications caused by COPD.
- Participant
- This review will encompass participants who were diagnosed as COPD in accordance with the criteria of GOLD. Restrictions are not placed on gender, age, and course of treatment. The following studies will be excluded: (1) cordyceps alone or in a formula used in combination with other nonoral herbal interventions; (2) cordyceps alone or in a formula used in combination with other Chinese medicine therapies, such as Qi Gong or acupuncture; (3) studies that included participants with respiratory failure, pulmonary hypertension, or corpulmonale; (4) studies in which the treatments were not recommended for COPD, for example, the studies using Bacille Calmette-Guerin or antibiotics as routine care.
- Animal
- Human Disease Modelled
- Intervention
- This review will encompass past studies comparing Bailing capsules, Jinshuibao capsule, and Zhiling capsule versus routine treatment (e.g., formoterol, indacaterol, tiotropium, and aclidinium). And then the network meta-analysis will be used to compare the efficacy between three drugs in the treatment of COPD.
- Comparator Control
- Routine care based on the guideline, nonpharmacological respiratory therapies, such as smoking cessation, pulmonary rehabilitation, oxygen therapy, and pulmonary exercise, will be included and used in both the treatment and control groups. Studies which used a wait list control or no treatment in the control arm were also included.
- Main Outcome
- The primary outcome measures were spirometric parameters (FEV1% predicted or FEV1/FVC ratio), six-minute walk distance (6MWD), St. George's Respiratory Questionnaire (SGRQ) total score, and frequency of exacerbation. Secondary outcome measures were effective rate, which is a global assessment of improvement in symptoms including dyspnea, mental status, appetite, and sweat according to chronic bronchitis section on the Guidance for Clinical Research on New Drugs of Traditional Chinese Medicine [16] and adverse events. Measures of effect None
- Outcome Measure
- Additional Outcome
- Not applicable
- Study Method
- Intervention, Meta-analysis, Network meta-analysis, Prevention, Systematic review
- Keyword
- Cordyceps; Humans; Powders; Pulmonary Disease, Chronic Obstructive; bailing capsules; zhiling
- Contact
- Yong Li [email protected]
- Organisational Affiliation
- Chengdu university of traditional chinese medicine https://www.cdutcm.edu.cn/
- Funding Source
- National Natural Science Foundation of China Grant number(s) State the funder, grant or award number and the date of award 81872959
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- China
- Review Stage
- Review Ongoing
- First Submission Date
- 2023-05-12
- Registration Date
- 2023-05-22
- Anticipated Start Date
- 2023-07-31
- Anticipated Completion Date
- 2023-06-30
- Title Cn
- 金水宝胶囊、百令胶囊与至灵胶囊治疗慢性阻塞性肺疾病(COPD)疗效的网状Meta分析
- Title En
- Efficacy of Jinshuibao capsule, Bailing capsule, and Zhiling capsule in the therapy of chronic obstructive pulmonary disease (COPD) based on network meta-analysis
- Bilingual Status
- complete